Stock Futures Rise Modestly; Rumble and Others Show Strong Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Rumble's New Business Unit: Rumble (RUM) shares surged 17% after the company launched a new business unit following its acquisition of Northern Data AG, with FY revenue outlook raised by approximately 30% to between €170 million and €190 million, enhancing its competitive position in the market.
- Smith & Wesson's Strong Earnings: Smith & Wesson Brands (SWBI) saw a 14% increase in shares after reporting a quarterly performance that exceeded expectations, with net sales up nearly 27% year-over-year and adjusted EBITDAS rising 31.7%, while planning investments in its Springfield facility for FY 2027 to boost capacity and operational efficiency.
- Spero Therapeutics Drug Approval: Spero Therapeutics (SPRO) shares rose 11% following FDA approval of Utebzi, developed in partnership with GSK, marking the first oral carbapenem therapy for complicated urinary tract infections, which is expected to significantly increase its market share.
- D-Wave's Quantum Computing Simulator: D-Wave Quantum (QBTS) shares gained 4% after unveiling its first gate-model quantum computing simulator designed for error-aware programming, representing a technological advancement that may attract more developers to its innovative solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEGN
Wall Street analysts forecast LEGN stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 33.380
Low
48.00
Averages
68.10
High
90.00
Current: 33.380
Low
48.00
Averages
68.10
High
90.00
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Legend Biotech Launches $225 Million Public Offering
- Offering Size: Legend Biotech has announced the commencement of a $225 million public offering of American Depositary Shares (ADSs), all of which will be offered by the company, reflecting its proactive fundraising strategy in the capital markets.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers for the offering, indicating the company's high standards and trust in the market when selecting underwriters.
- Additional Option: The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the ADSs, enhancing the offering's flexibility and potential fundraising capacity.
- Market Condition Impact: The offering is subject to market conditions, and while uncertainties exist, the company is committed to leveraging this financing to advance CAR-T cell therapy development, thereby strengthening its leadership position in cancer treatment.
See More
Stock Futures Rise Modestly; Rumble and Others Show Strong Performance
- Rumble's New Business Unit: Rumble (RUM) shares surged 17% after the company launched a new business unit following its acquisition of Northern Data AG, with FY revenue outlook raised by approximately 30% to between €170 million and €190 million, enhancing its competitive position in the market.
- Smith & Wesson's Strong Earnings: Smith & Wesson Brands (SWBI) saw a 14% increase in shares after reporting a quarterly performance that exceeded expectations, with net sales up nearly 27% year-over-year and adjusted EBITDAS rising 31.7%, while planning investments in its Springfield facility for FY 2027 to boost capacity and operational efficiency.
- Spero Therapeutics Drug Approval: Spero Therapeutics (SPRO) shares rose 11% following FDA approval of Utebzi, developed in partnership with GSK, marking the first oral carbapenem therapy for complicated urinary tract infections, which is expected to significantly increase its market share.
- D-Wave's Quantum Computing Simulator: D-Wave Quantum (QBTS) shares gained 4% after unveiling its first gate-model quantum computing simulator designed for error-aware programming, representing a technological advancement that may attract more developers to its innovative solutions.
See More
Legend Biotech Prices Public Offering of 7.7M ADSs
- Offering Size: Legend Biotech has announced the pricing of 7.7 million American Depositary Shares (ADSs) at $29.35 each, with total gross proceeds expected to be approximately $226 million, which will significantly bolster the company's capital structure.
- Underwriter Arrangement: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are acting as joint book-running managers for the transaction, indicating strong market confidence in the company's financing capabilities and laying the groundwork for future capital operations.
- Overallotment Option: Legend Biotech has granted underwriters a 30-day overallotment option to purchase up to an additional 1.16 million ADSs at the public offering price, providing the company with flexibility for further financing.
- Market Reaction: Following the announcement of the offering, Legend Biotech's shares fell 6% in after-hours trading on Wednesday, reflecting a cautious market sentiment regarding the financing, which may impact the company's short-term stock performance.
See More
Legend Biotech Prices Public Offering at $29.35 per ADS
- Offering Size: Legend Biotech has priced its public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 each, raising approximately $226 million in gross proceeds before underwriting discounts and expenses, indicating strong demand in the capital markets.
- Underwriter Arrangement: The offering is managed by Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities, with underwriters granted a 30-day option to purchase an additional 1.155 million ADSs at the offering price, which enhances market confidence in the transaction.
- Transaction Timeline: The offering is expected to close on June 23, 2026, subject to customary closing conditions, providing investors with a clear timeline that aids in market transparency and planning.
- Market Performance: Over the past year, LEGN shares have traded between $16.24 and $45.30, closing at $33.52, although they fell 5.43% to $31.70 in overnight trading, yet the overall performance reflects a degree of market vitality.
See More
Legend Biotech Prices Public Offering of ADSs
- Offering Size: Legend Biotech has priced its public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 each, aiming for gross proceeds of approximately $226 million, reflecting strong market demand for its cell therapies.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank are serving as joint book-running managers for the offering, indicating the company's credibility and attractiveness in the capital markets, further solidifying its leadership in the cell therapy sector.
- Additional Option: The company has granted underwriters a 30-day option to purchase an additional 1,155,000 ADSs at the same price, a strategy that could enhance total fundraising and increase financial flexibility.
- Market Outlook: The offering is expected to close on June 23, 2026, and if successful, will provide funding for Legend Biotech's future innovations and expansions, supporting its ongoing development in the CAR-T cell therapy space.
See More
Legend Biotech Launches $225 Million Public Offering of ADS
- Offering Size: Legend Biotech has commenced an underwritten public offering of $225 million in American depositary shares (ADS), with each ADS representing two ordinary shares, indicating the company's need for capital in the market.
- Underwriters' Option: The company plans to grant underwriters a 30-day option to purchase up to 15% additional ADSs, which, if fully exercised, could increase the total offering size beyond $225 million, thereby providing more financial support for the company.
- Market Reaction: Following the announcement of the public offering, Legend Biotech's shares fell 6% in after-hours trading, reflecting a cautious market sentiment regarding the offering, which may impact investor confidence.
- Industry Context: This offering occurs against the backdrop of the Federal Reserve's hawkish monetary policy, raising concerns about valuations in tech and biotech stocks, potentially leading to reduced demand for new stock issuances.
See More
Legend Biotech Launches $225 Million Public Offering
- Offering Size: Legend Biotech has announced the commencement of a $225 million public offering of American Depositary Shares (ADSs), all of which will be offered by the company, reflecting its proactive fundraising strategy in the capital markets.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers for the offering, indicating the company's high standards and trust in the market when selecting underwriters.
- Additional Option: The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the ADSs, enhancing the offering's flexibility and potential fundraising capacity.
- Market Condition Impact: The offering is subject to market conditions, and while uncertainties exist, the company is committed to leveraging this financing to advance CAR-T cell therapy development, thereby strengthening its leadership position in cancer treatment.
See More
Stock Futures Rise Modestly; Rumble and Others Show Strong Performance
- Rumble's New Business Unit: Rumble (RUM) shares surged 17% after the company launched a new business unit following its acquisition of Northern Data AG, with FY revenue outlook raised by approximately 30% to between €170 million and €190 million, enhancing its competitive position in the market.
- Smith & Wesson's Strong Earnings: Smith & Wesson Brands (SWBI) saw a 14% increase in shares after reporting a quarterly performance that exceeded expectations, with net sales up nearly 27% year-over-year and adjusted EBITDAS rising 31.7%, while planning investments in its Springfield facility for FY 2027 to boost capacity and operational efficiency.
- Spero Therapeutics Drug Approval: Spero Therapeutics (SPRO) shares rose 11% following FDA approval of Utebzi, developed in partnership with GSK, marking the first oral carbapenem therapy for complicated urinary tract infections, which is expected to significantly increase its market share.
- D-Wave's Quantum Computing Simulator: D-Wave Quantum (QBTS) shares gained 4% after unveiling its first gate-model quantum computing simulator designed for error-aware programming, representing a technological advancement that may attract more developers to its innovative solutions.
See More
Legend Biotech Prices Public Offering of 7.7M ADSs
- Offering Size: Legend Biotech has announced the pricing of 7.7 million American Depositary Shares (ADSs) at $29.35 each, with total gross proceeds expected to be approximately $226 million, which will significantly bolster the company's capital structure.
- Underwriter Arrangement: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are acting as joint book-running managers for the transaction, indicating strong market confidence in the company's financing capabilities and laying the groundwork for future capital operations.
- Overallotment Option: Legend Biotech has granted underwriters a 30-day overallotment option to purchase up to an additional 1.16 million ADSs at the public offering price, providing the company with flexibility for further financing.
- Market Reaction: Following the announcement of the offering, Legend Biotech's shares fell 6% in after-hours trading on Wednesday, reflecting a cautious market sentiment regarding the financing, which may impact the company's short-term stock performance.
See More
Legend Biotech Prices Public Offering at $29.35 per ADS
- Offering Size: Legend Biotech has priced its public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 each, raising approximately $226 million in gross proceeds before underwriting discounts and expenses, indicating strong demand in the capital markets.
- Underwriter Arrangement: The offering is managed by Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities, with underwriters granted a 30-day option to purchase an additional 1.155 million ADSs at the offering price, which enhances market confidence in the transaction.
- Transaction Timeline: The offering is expected to close on June 23, 2026, subject to customary closing conditions, providing investors with a clear timeline that aids in market transparency and planning.
- Market Performance: Over the past year, LEGN shares have traded between $16.24 and $45.30, closing at $33.52, although they fell 5.43% to $31.70 in overnight trading, yet the overall performance reflects a degree of market vitality.
See More
Legend Biotech Prices Public Offering of ADSs
- Offering Size: Legend Biotech has priced its public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 each, aiming for gross proceeds of approximately $226 million, reflecting strong market demand for its cell therapies.
- Underwriter Selection: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank are serving as joint book-running managers for the offering, indicating the company's credibility and attractiveness in the capital markets, further solidifying its leadership in the cell therapy sector.
- Additional Option: The company has granted underwriters a 30-day option to purchase an additional 1,155,000 ADSs at the same price, a strategy that could enhance total fundraising and increase financial flexibility.
- Market Outlook: The offering is expected to close on June 23, 2026, and if successful, will provide funding for Legend Biotech's future innovations and expansions, supporting its ongoing development in the CAR-T cell therapy space.
See More
Legend Biotech Launches $225 Million Public Offering of ADS
- Offering Size: Legend Biotech has commenced an underwritten public offering of $225 million in American depositary shares (ADS), with each ADS representing two ordinary shares, indicating the company's need for capital in the market.
- Underwriters' Option: The company plans to grant underwriters a 30-day option to purchase up to 15% additional ADSs, which, if fully exercised, could increase the total offering size beyond $225 million, thereby providing more financial support for the company.
- Market Reaction: Following the announcement of the public offering, Legend Biotech's shares fell 6% in after-hours trading, reflecting a cautious market sentiment regarding the offering, which may impact investor confidence.
- Industry Context: This offering occurs against the backdrop of the Federal Reserve's hawkish monetary policy, raising concerns about valuations in tech and biotech stocks, potentially leading to reduced demand for new stock issuances.
See More
